<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Ophthalmic gases - Moria - Alchimia</title>
	<atom:link href="https://alchimiasrl.com/information/ophthalmic-surgery/ophthalmic-gases/feed/" rel="self" type="application/rss+xml" />
	<link>https://alchimiasrl.com/information/ophthalmic-surgery/ophthalmic-gases/</link>
	<description>Your ideas, our solutions</description>
	<lastBuildDate>Wed, 19 May 2021 16:34:58 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://alchimiasrl.com/wp-content/uploads/2020/03/cropped-Icon-per-sito-32x32.jpg</url>
	<title>Ophthalmic gases - Moria - Alchimia</title>
	<link>https://alchimiasrl.com/information/ophthalmic-surgery/ophthalmic-gases/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>25-gauge vitrectomy with gas tamponade for rhegmatogenous retinal detachment: experienced vs. Inexperienced surgeons</title>
		<link>https://alchimiasrl.com/25-gauge-vitrectomy-with-gas-tamponade-for-rhegmatogenous-retinal-detachment-experienced-vs-inexperienced-surgeons/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Wed, 17 Feb 2021 10:22:51 +0000</pubDate>
				<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[home]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=20981</guid>

					<description><![CDATA[<p>Year: 2021 Authors: Pencak M.; Veith M.; Stranak Z.; Dite J.; Vranova J.; Studeny P.     Preprint 10.21203/rs.3.rs-53301/v3 Online version This is a: Preprint   Introduction: To compare the results and complication rates of a 25-gauge pars plana vitrectomy (PPV) with gas tamponade for rhegmatogenous retinal detachment (RRD) between experienced and  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/25-gauge-vitrectomy-with-gas-tamponade-for-rhegmatogenous-retinal-detachment-experienced-vs-inexperienced-surgeons/">25-gauge vitrectomy with gas tamponade for rhegmatogenous retinal detachment: experienced vs. Inexperienced surgeons</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-1"><p><strong>Year:</strong> 2021</p>
<p><strong>Authors</strong>: Pencak M.; Veith M.; Stranak Z.; Dite J.; Vranova J.; Studeny P.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-2"><p>Preprint<br />
10.21203/rs.3.rs-53301/v3<br />
<a href="https://www.researchsquare.com/article/rs-53301/v3">Online version</a></p>
</div><div class="fusion-text fusion-text-3"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Preprint</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-4"><div class="align-m">
<p><strong>Introduction:</strong> To compare the results and complication rates of a 25-gauge pars plana vitrectomy (PPV) with gas tamponade for rhegmatogenous retinal detachment (RRD) between experienced and inexperienced surgeons.</p>
</div>
<div class="collapsable-text readability is-active">
<p><strong>Materials and Methods:</strong> This is a retrospective comparative consecutive case series study of patients with uncomplicated RRD treated with 25g PPV with gas tamponade. Patients were divided into 2 groups: In experienced surgeon group (ESG) the procedure was performed by an experienced vitreoretinal surgeon and in inexperienced surgeon group (ISG) the procedure was performed by 2 inexperienced surgeons. Anatomical and functional results and complication rates were compared between the two groups.</p>
<p><strong>Results:</strong> 216 eyes were included in the study. In the ESG (106 eyes), the single operation success rate was 94.3%, and the final success rate was 100%. In the ISG (110 eyes), the single operation success rate was 93.6%, and the final success rate was 100.0%. The difference in single surgery success rate between groups was not statistically significant (P = 0.828). The mean postoperative BCVA improvement was 0.348 decimal in ESG and 0.405 decimal in ISG (P = 0.234). The difference in complication rates between groups was not significant.</p>
<p><strong>Conclusions:</strong> A 25g PPV with gas tamponade for treatment of RRD yields excellent anatomical results and improvement in BCVA. With good technique and use of modern vitrectomy machines and instruments, even inexperienced surgeons can achieve high single operation success rate, suggesting a short learning curve. The complication rate is comparable between experienced and inexperienced surgeons.</p>
</div>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/25-gauge-vitrectomy-with-gas-tamponade-for-rhegmatogenous-retinal-detachment-experienced-vs-inexperienced-surgeons/">25-gauge vitrectomy with gas tamponade for rhegmatogenous retinal detachment: experienced vs. Inexperienced surgeons</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals</title>
		<link>https://alchimiasrl.com/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Mon, 24 Sep 2018 16:46:29 +0000</pubDate>
				<category><![CDATA[EURETINA]]></category>
		<category><![CDATA[HPF]]></category>
		<category><![CDATA[Meeting presentations]]></category>
		<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[R&D Presentations]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=13329</guid>

					<description><![CDATA[<p>Year: 2018, Euretina Authors: Romano M. Co-Authors: Gatto C.; Giurgola L.; Ferrara M.; D'Amato Tóthová J.   Methods: Serial dilutions of perfluorooctanoid acid, 1H,1H,7H-dodecafluoro-1- heptanol, 1H,1H,1H,2H,2H-Perfluorooctane, 1H perfluorooctan; ethylbenzene, paraxylene, perfluotobutyfurane, and hexafluoro-1,2,3,4-tetrachlorobutane were tested by direct contact cytotoxicity test using BALB3T3 and ARPE19 cell lines, after application on 59% of the area for 24 h.  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/">Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-2 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-1 hover-type-none"><img decoding="async" width="200" height="200" title="Euretina 200" src="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png" alt class="img-responsive wp-image-12355" srcset="https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-66x66.png 66w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-100x100.png 100w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3-150x150.png 150w, https://alchimiasrl.com/wp-content/uploads/2018/11/Euretina-200-3.png 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-5"><p><strong>Year:</strong> 2018, Euretina</p>
<p><strong>Authors</strong>: Romano M.</p>
<p><strong>Co-Authors</strong>: Gatto C.; Giurgola L.; Ferrara M.; D&#8217;Amato Tóthová J.</p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-6"><p><strong> <span class="fontstyle0">Methods</span><span class="fontstyle0">: </span></strong><span class="fontstyle0">Serial dilutions of perfluorooctanoid acid, 1H,1H,7H-dodecafluoro-1- heptanol, 1H,1H,1H,2H,2H-Perfluorooctane, 1H perfluorooctan; ethylbenzene, paraxylene, perfluotobutyfurane, and hexafluoro-1,2,3,4-tetrachlorobutane were tested by direct contact cytotoxicity test using BALB3T3 and ARPE19 cell lines, after application on 59% of the area for 24 h.<br />
</span></p>
<p><strong><span class="fontstyle0">Results</span></strong><span class="fontstyle0"><strong>:</strong> </span><span class="fontstyle0">Traces of paraxylene, ethylbenzene, and PFOA (≤30ppm) induced severe toxicity in both cell lines. Hexafluoro-1,2,3,4-tetrachlorobutane and H,1H,7H-Dodecafluoro-1-heptanol were cytotoxic at approximately 10000 ppm. 1H perfluorooctan was cytotoxic at approximately 60000 ppm. High concentrations of 1H,1H,1H,2H,2H-Perfluorooctane and perfluotobutyfurane were not cytotoxic.<br />
</span></p>
<p><strong><span class="fontstyle0">Conclusions</span></strong><span class="fontstyle0"><strong>:</strong> S</span><span class="fontstyle0">ix out of eight perfluorocarbon manufacturing process residuals showed cytotoxicity in the direct contact test according to ISO 10993-5. Paraxylene, ethylbenzene, and PFOA were the most cytotoxic compounds. 1H,1H,1H,2H,2H-Perfluorooctane and perfluotobutyfurane were not cytotoxic.</span></p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/cytotoxicity-testing-according-to-iso-10993-5-of-perfluorocarbon-manufacturing-process-residuals/">Cytotoxicity testing according to ISO 10993-5 of perfluorocarbon manufacturing process residuals</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>25-gauge vitrectomy and gas for the management of rhegmatogenous retinal detachment</title>
		<link>https://alchimiasrl.com/25-gauge-vitrectomy-and-gas-for-the-management-of-rhegmatogenous-retinal-detachment/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Thu, 21 Jun 2018 09:45:46 +0000</pubDate>
				<category><![CDATA[GOT]]></category>
		<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=15492</guid>

					<description><![CDATA[<p>Year: 2018 Authors: Veitha M.; Stranaka Z.; Pencaka M.; Vranovab J.; Studenya P.     Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia (Biomed Paper) doi: 10.5507/bp.2018.034 Online version This is a: Publication   Aims: To evaluate the anatomical and functional results in patients with rhegmatogenous retinal detachment  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/25-gauge-vitrectomy-and-gas-for-the-management-of-rhegmatogenous-retinal-detachment/">25-gauge vitrectomy and gas for the management of rhegmatogenous retinal detachment</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-3 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-image-element fusion-image-align-center in-legacy-container" style="text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);"><div class="imageframe-align-center"><span class=" fusion-imageframe imageframe-none imageframe-2 hover-type-none"><img decoding="async" width="200" height="200" title="Biomedical papers" src="https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers.jpg" alt class="img-responsive wp-image-15493" srcset="https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers-66x66.jpg 66w, https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers-100x100.jpg 100w, https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers-150x150.jpg 150w, https://alchimiasrl.com/wp-content/uploads/2019/04/Biomedical-papers.jpg 200w" sizes="(max-width: 200px) 100vw, 200px" /></span></div></div><div class="fusion-text fusion-text-7"><p><strong>Year: </strong>2018</p>
<p><strong>Authors</strong>: Veitha M.; Stranaka Z.; Pencaka M.; Vranovab J.; Studenya P.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-8"><p>Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia (Biomed Paper)<br />
doi: 10.5507/bp.2018.034<br />
<a href="https://www.researchgate.net/publication/326151044_25-gauge_vitrectomy_and_gas_for_the_management_of_rhegmatogenous_retinal_detachment">Online version</a></p>
</div><div class="fusion-text fusion-text-9"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-10"><p><strong>Aims:</strong> To evaluate the anatomical and functional results in patients with rhegmatogenous retinal detachment (RRD) who underwent 25-gauge pars plana vitrectomy (PPV) with gas tamponade.</p>
<p><strong>Materials and Methods:</strong> A retrospective evaluation of 126 eyes of 126 patients (79 men, 47 women) with RRD who underwent 25-gauge PPV with gas tamponade (13% C3F8 in 87 eyes, 20% SF6 in 39 eyes). 113 patients (89.7%), were operated on under local anaesthesia, 13 patients (10.3%) under general anaesthesia. Macula was detached in 85 eyes (67.5%). 53 eyes had pseudophakic RRD, 73 eyes were phakic. Anatomical success of the primary intervention, change in best corrected visual acuity (BCVA) and incidence of complications were assessed. An average follow-up period is 7.2 months (6-15).</p>
<p><strong>Results:</strong> With single operation, retinal attachment was achieved in 125 eyes (99.2%); the final anatomical success was 100%. The initial mean BCVA was 0.89 logMar (2.00 to 0.00); at the end of the follow-up period, it improved to 0.23logMAR (1.00 to -0.10), P &lt; 0,0001. During the first post-intervention day, hypotony of the eye below 10 mmHg was observed in 1 patient (0.8%); on the contrary, intraocular pressure was temporarily increased to 25 mmHg and more in 36 patients (28.6%).</p>
<p><strong>Conclusion:</strong> The surgical treatment of RRD using 25-gauge PPV with expansive gas tamponade renders excellent anatomical results and improvement in BCVA. The incidence of complications and necessity of sclerotomy suturing are low.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/25-gauge-vitrectomy-and-gas-for-the-management-of-rhegmatogenous-retinal-detachment/">25-gauge vitrectomy and gas for the management of rhegmatogenous retinal detachment</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Thirteen-Year Vitreoretinal Surgical Outcomes of 5,097 Cases from a Tertiary Referral Center in Turkey</title>
		<link>https://alchimiasrl.com/thirteen-year-vitreoretinal-surgical-outcomes-of-5097-cases-from-a-tertiary-referral-center-in-turkey/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Mon, 28 Oct 2013 15:48:20 +0000</pubDate>
				<category><![CDATA[GOT]]></category>
		<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=12752</guid>

					<description><![CDATA[<p>Year: 2013 Authors: Teke M.Y.; Balikogly-Yilmaz M.; Yuksekkaya P.; Citirik M.; Elgin U.; Ozdal P.; Yenigun S.; Sen E.; Ozturk F.     Opthalmologica 230: 186-94, 2013 Online version  This is a: Publication   Abstract: A 13-year retrospective chart review of 5,097 consecutive cases that underwent pars plana vitrectomy (PPV), and retinal  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/thirteen-year-vitreoretinal-surgical-outcomes-of-5097-cases-from-a-tertiary-referral-center-in-turkey/">Thirteen-Year Vitreoretinal Surgical Outcomes of 5,097 Cases from a Tertiary Referral Center in Turkey</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-4 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-11"><p><strong>Year: </strong>2013</p>
<p><strong>Authors</strong>: Teke M.Y.; Balikogly-Yilmaz M.; Yuksekkaya P.; Citirik M.; Elgin U.; Ozdal P.; Yenigun S.; Sen E.; Ozturk F.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-12"><p>Opthalmologica 230: 186-94, 2013<br />
<a href="http://www.ncbi.nlm.nih.gov/pubmed/24080789">Online version</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-13"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-14"><p><strong>Abstract: </strong>A 13-year retrospective chart review of 5,097 consecutive cases that underwent pars plana vitrectomy (PPV), and retinal tamponade with GOT SF6 multi or GOT C3F8 (AL.CHI.MI.A. S.r.l.) according to the specific case, in a tertiary referral center in Turkey was performed. Age at onset, sex, laterality, associated systemic diseases, pre- and postoperative visual acuities (VA), indications, type of surgery and outcome of surgery were analyzed. The most common indications for vitreoretinal surgery (VRS) were rhegmatogenous retinal detachment (n = 1,802, 35.4%) and proliferative diabetic retinopathy (n 0 1,505, 29.5%). The most common vitreoretinal technique combinations performed were PPV with encircling endolaser (EL) and phacoemulsification with intraocular lens implantation (33,0%)., PPV with encircling EL (30.4%), and only PPV (7.0%). A statistically significant increase in the mean VA was noted at the first- (1.16 ± 0.44 logarithm of the minimum angle of resolution, logMAR) and sixth-month (1.06 ± 0.61 logMAR) visits when compared to the preoperative VA (1.77 ± 0.58 logMAR; p &lt;  0.001). Comparisons in the top surgical indications, techniques and outcomes for vitrectomy between the countries could be important for the development of subspecialization in VRS.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/thirteen-year-vitreoretinal-surgical-outcomes-of-5097-cases-from-a-tertiary-referral-center-in-turkey/">Thirteen-Year Vitreoretinal Surgical Outcomes of 5,097 Cases from a Tertiary Referral Center in Turkey</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Interaction between Perfluorocarbon Liquid and Heavy Silicone Oil: Risk Factor for “Sticky Oil” Formation</title>
		<link>https://alchimiasrl.com/interaction-between-perfluorocarbon-liquid-and-heavy-silicone-oil-risk-factor-for-sticky-oil-formation/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Sat, 28 Jul 2012 15:28:05 +0000</pubDate>
				<category><![CDATA[HPF]]></category>
		<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=12742</guid>

					<description><![CDATA[<p>Year: 2012  Authors: Romano M.R.; Vallejo-Garcia J.L.; Parmeggiani F.; Vito R.; Vinciguerra P.     Curr Eye Res. 37(7): 563-6, 2012 Online version  This is a: Publication   Abstract: Interactions between perfluoro-n-octane (PFO) or perfluorodecalin (PFD) and heavy silicone oil (HSO, either alkane or ether) were studied in vitro by incubating fluids  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/interaction-between-perfluorocarbon-liquid-and-heavy-silicone-oil-risk-factor-for-sticky-oil-formation/">Interaction between Perfluorocarbon Liquid and Heavy Silicone Oil: Risk Factor for “Sticky Oil” Formation</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-5 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-15"><p><strong>Year: </strong>2012<strong> </strong></p>
<p><strong>Authors</strong>: Romano M.R.; Vallejo-Garcia J.L.; Parmeggiani F.; Vito R.; Vinciguerra P.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-16"><p>Curr Eye Res. 37(7): 563-6, 2012<br />
<a href="http://www.ncbi.nlm.nih.gov/pubmed/22578277">Online version</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-17"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-18"><p><strong>Abstract: </strong>Interactions between perfluoro-n-octane (PFO) or perfluorodecalin (PFD) and heavy silicone oil (HSO, either alkane or ether) were studied in vitro by incubating fluids for 7 days at regulated temperatures.</p>
<p>The samples were divided into two groups: Group A, PFCL (PFO or PFD) + 5 ml of HSO (silicone oil + alkane or ether); Group B, HSO (silicone oil + alkane or ether) without perfluorocarbons (PFCLs).</p>
<p>Each sample was kept at 36°C for 7 days. HSOs were then removed with a 20 G, 7 mm-long cannula under 600 mm Hg of vacuum pressure at two different temperatures: 36 and 22°C. The time needed to remove the oils and the presence of opacity was recorded. Each experiment was performed in triplicate. In vitro, interactions between PFCLs and HSO oil led to the formation of hyper-viscous solutions with significant increase in aspiration time in Group A. (P = 0.006, Kruskal–Wallis test). Temperature was also found to affect HSOs’ saturation, as a decrease in temperature determined an increase in opacity and shear viscosity of the solution (P = 0.02, Kruskal–Wallis test).</p>
<p>No differences between alkane and ether (P = 0.74) and perfluoro-n-octane and perfluorodecalin (P=0.56) was found. In conclusion, interactions between PFCL–HSO and variation in temperature lead to the formation of hyper-viscous solutions that could be described as “sticky oil”.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/interaction-between-perfluorocarbon-liquid-and-heavy-silicone-oil-risk-factor-for-sticky-oil-formation/">Interaction between Perfluorocarbon Liquid and Heavy Silicone Oil: Risk Factor for “Sticky Oil” Formation</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Primary 23-gauge vitreoretinal surgery for rhegmatogenous retinal detachment</title>
		<link>https://alchimiasrl.com/primary-23-gauge-vitreoretinal-surgery-for-rhegmatogenous-retinal-detachment/</link>
		
		<dc:creator><![CDATA[Michela Stocco]]></dc:creator>
		<pubDate>Mon, 28 May 2012 15:47:11 +0000</pubDate>
				<category><![CDATA[GOT]]></category>
		<category><![CDATA[Ophthalmic gases]]></category>
		<category><![CDATA[Ophthalmic surgery products]]></category>
		<category><![CDATA[Publications]]></category>
		<guid isPermaLink="false">https://alchimiasrl.com/?p=12750</guid>

					<description><![CDATA[<p>Year: 2012 Authors: Yanyali A.; Celik G.; Dincyildiz A.; Horozoglu F.; Nohutcu A.F.     Int J Ophthalmol. 5(2): 226–230, 2012 Online version  This is a: Publication   Abstract: We evaluated 49 eyes of 49 consecutive patients who underwent primary 23-G transconjunctival sutureless vitrectomy (TSV) for RRD between January 2007 and July  [...]</p>
<p>L'articolo <a href="https://alchimiasrl.com/primary-23-gauge-vitreoretinal-surgery-for-rhegmatogenous-retinal-detachment/">Primary 23-gauge vitreoretinal surgery for rhegmatogenous retinal detachment</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-6 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-10 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-first" style="--awb-bg-size:cover;width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-right: 4%;"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-19"><p><strong>Year: </strong>2012</p>
<p><strong>Authors</strong>: Yanyali A.; Celik G.; Dincyildiz A.; Horozoglu F.; Nohutcu A.F.</p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:0px;margin-bottom:0px;width:100%;"><div class="fusion-separator-border sep-single sep-solid" style="--awb-height:20px;--awb-amount:20px;border-color:#e0dede;border-top-width:1px;"></div></div><div class="fusion-sep-clear"></div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:15px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-20"><p>Int J Ophthalmol. 5(2): 226–230, 2012<br />
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359044/">Online version</a></p>
</div><div class="fusion-sep-clear"></div><div class="fusion-separator fusion-full-width-sep" style="margin-left: auto;margin-right: auto;margin-top:5px;width:100%;"></div><div class="fusion-sep-clear"></div><div class="fusion-text fusion-text-21"><p><span style="float: left; padding-top: 8px;">This is a: </span><span style="font-size: 14px; width: 150px; padding: 8px; display: inline-block; margin-bottom: 40px; color: white; background-color: #002f59; padding-left: 15px; margin-left: 10px;">Publication</span></p>
</div><div class="fusion-clearfix"></div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-11 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-last" style="--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );"><div class="fusion-column-wrapper fusion-flex-column-wrapper-legacy"><div class="fusion-text fusion-text-22"><p><strong>Abstract: </strong>We evaluated 49 eyes of 49 consecutive patients who underwent primary 23-G transconjunctival sutureless vitrectomy (TSV) for RRD between January 2007 and July 2009.</p>
<p>The internal tamponades used in the treatment of RRD included GOT SF6 multi and GOT C3F8 multi (Alchimia, Ponte S. Nicolò, Italy).<br />
Mean follow-up time was 8.9 ± 7.7 months (1-28 months). Retinal reattachment was achieved with a single operation in 47 (95.9%) of 49 eyes.</p>
<p>Mean logMAR visual acuity was 2.01 ± 0.47 preoperatively and 1.3 ± 0.5 postoperatively. Mean preoperative intraocular pressure (IOP) was 14.1 ± 2.8 mmHg.</p>
<p>Mean postoperative IOP was 12.3 ± 3.6 mmHg at 1 day, 13.1 ± 2.1 mmHg at 1 week, 14.3 ± 2.2 mmHg at 1 month. Iatrogenic peripheral retinal break was observed in 1 eye (2.0% ) intraoperatively. No sutures were required to close the scleral or conjunctival openings, and no eyes required convertion of surgery to 20-G vitrectomy.</p>
<p>Primary 23-G TSV system was observed to be effective and safe in the treatment of RRD.</p>
</div><div class="fusion-clearfix"></div></div></div></div></div>
<p>L'articolo <a href="https://alchimiasrl.com/primary-23-gauge-vitreoretinal-surgery-for-rhegmatogenous-retinal-detachment/">Primary 23-gauge vitreoretinal surgery for rhegmatogenous retinal detachment</a> proviene da <a href="https://alchimiasrl.com">Moria - Alchimia</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
